Dr. Pinilla-Ibarz on the Benefit of BTK Inhibitors in CLL

Javier Pinilla-Ibarz, MD, PhD, senior member, head of Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia (CLL).

Since patients with any risk factors can receive BTK inhibitors, they have become an important therapeutic strategy within CLL, Pinilla-Ibarz says. Furthermore, BTK inhibitors are accessible to patients without the need for close monitoring, making it easier for patients to receive this treatment, Pinilla-Ibarz explains.

One of the key challenges in CLL is identifying the right BTK inhibitor for each individual patient, based on their disease and the adverse effects associated with each agent, Pinilla-Ibarz adds. Overall, BTK inhibitors allow patients to receive effective treatment while maintaining a good quality of life, Pinilla-Ibarz concludes.